Rein Therapeutics, Inc. (RNTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.71
- As of
Kresmion compiles this page from RNTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Rein Therapeutics, Inc. (RNTX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-04.
See the full RNTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RNTX on one page. Preview it with sample data, then open it live with a free account.
Preview the RNTX dossierActive events for RNTX
- mediumEarnings above estimates
Q2-2026: Beat consensus by 42.3%, EPS $-0.10 vs $-0.1734 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +1931% to RNTX (2026Q2)
- mediumEarnings below estimates
Q2-2025: Missed consensus by 24.8% - EPS $-0.28 vs $-0.2244 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 14.2% - EPS $-0.21 vs $-0.2448 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 398.1% - EPS $-1.0923 vs $-0.2193 estimate
FREE, NO ACCOUNT
Every event on RNTX, as it fires
You are seeing 5 of 6 events recorded on RNTX since 2026-05-17.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RNTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 00887A204 · 2026Q2 | $2.5M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00887A204 · 2026Q2 | $20K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RNTX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RNTX against its peers
RNTX's return on equity of -294.8% ranks in the 18th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | RNTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 813455 USD | 7 | 13 |
| Operating margin | n/a | -3536.5% | n/a | 12 |
| Net margin | n/a | -3449.0% | n/a | 12 |
| Return on equity | -294.8% | -109.5% | 18 | 18 |
Peers (24): GANX, HOWL, SGMOQ, LONA, ELTX, CNTB, ELOX, INKT, IMA, BMEA, MREO, BOLD, OSTX, HRTX, ATNM, ALDX, CRBU, XLO, HYPD, GOSS, VRCA, ATHE, KLRS, SER. Left out: APLM (period gap). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (RNTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RNTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RNTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.